stockrow
Monday 9 November 2026
Export NGEN’s income statement to Excel — free account
NervGen Pharma Corp.
NGEN- EPS
- +192.2%
- Free cash flow
- −48.1%
Quarter to June 2026, against a year earlier
1.33
0.01
+0.76%
Follow NGEN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
2.07 | 1.34 | 1.32 | 0.79 |
+3 more quarters Free account |
Net Debt/EBITDA |
7.33 | 2.20 | 4.79 | 1.85 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
(0.52) | 4.89 | 0.23 | 1.29 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.02 | 0.02 | 0.03 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.04) | (0.07) | (0.06) | (0.05) | |
Cash per Share |
0.68 | 0.15 | 0.22 | 0.11 | |
Shareholders Equity per Share |
0.37 | 0.05 | 0.06 | (0.03) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.37 | 0.05 | 0.06 | (0.03) | |
Free Cash Flow |
(4.09) | (5.98) | (4.44) | (3.88) | |
Working Capital |
33.56 | 3.75 | 3.93 | (2.44) | |
Net Current Asset Value |
33.56 | 3.75 | 3.93 | (2.44) | |
| Other line items | |||||
Quick Ratio |
2.01 | 1.09 | 1.28 | 0.73 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.04) | (0.07) | (0.06) | (0.05) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Receivables |
0.11 | 0.15 | 0.18 | — | |
Average Payables |
3.44 | 3.71 | 3.47 | — | |
Average Assets |
38.69 | 13.08 | 15.42 | — | |
Average Common Equity |
16.58 | 2.50 | 3.05 | — |
Columns are period end dates · fundamentals updated 2 Nov 2026